Leadership

Dr. Cyrus D. Mozayeni is co-founder, President and CEO of Vedere Bio and Entrepreneur-in-Residence at Atlas Venture. Prior to Vedere, he was co-founder of CODA Biotherapeutics, and Oncorus (NASDAQ: ONCR) where he served as President and CBO. Prior to Oncorus, Cyrus served as VP and global head of business development and alliance management at bluebird bio (NASDAQ: BLUE), where his efforts led to a clinical-stage CAR T-cell program (ABECMA®, idecabtagene vicleucel) in collaboration with Celgene, and a successful IPO. Cyrus earned his Sc.B. in neuroscience from Brown University, his M.D. from the University of Virginia School of Medicine and his MBA from the Kellogg School of Management at Northwestern University. He is a licensed physician, and a Fellow of the Academy of Wilderness Medicine.

Ms. Gina Consylman brings over 25 years of experience in finance, accounting, investor relations, strategy, and corporate development to Vedere. Before joining Vedere, Gina served as CFO of bluebird bio where she oversaw financial activities during the company’s transition into two independent entities. Prior to bluebird bio, she spent more than seven years at Ironwood Pharmaceutics, Inc., in roles of increasing responsibilities, culminating in the role of SVP, Chief Financial Officer. There, she was responsible for driving financial strategy through early to late-stage clinical evaluation and commercialization of multiple drug product candidates and products, as well as navigating multiple high-value collaborations with pharmaceutical companies. Gina was also Vice President, Corporate Controller and Principal Accounting Officer at Analogic Corporation, where she oversaw the company’s global accounting team. Additionally, she served as Senior Director of Corporate Accounting at Biogen Inc., where she led the accounting teams for the corporate and U.S. commercial business units. Gina currently serves on the board of directors for Assembly Biosciences, Inc., and holds a B.S. in accounting from Johnson & Wales University and a M.S. in taxation from Bentley University. 

Dr. Anna Demetriades is a board-certified ophthalmologist with over 20 years of experience in clinical ophthalmology and ocular gene therapy research as well as ophthalmic drug development from her time at Genentech. Prior to Vedere, Dr. Demetriades served as the lead clinician for VABSYMO® (faricimab-svoa) in neovascular age-related macular degeneration at Genentech (a member of the Roche Group), where she played a key role in the successful completion of the Phase III clinical program and global regulatory approval process, including the recent FDA (United States) and MHLW (Japan) approvals and regulatory submissions to the EMA (Europe) and Access Consortium. Prior to Genentech, Dr. Demetriades served as Chief of the Glaucoma Service at Weill Cornell Medicine, New York Presbyterian Hospital for five years and as an Assistant Professor of Ophthalmology for ten years. During that time, she led a research laboratory focused on AAV-mediated neuroprotective gene therapy for glaucoma. Dr. Demetriades completed her ophthalmology residency at The Wilmer Eye Institute, Johns Hopkins Hospital and her glaucoma clinical fellowship at The Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. She completed a retina research fellowship at The Wilmer Eye Institute, Johns Hopkins Hospital and received her Ph.D. in ocular gene therapy for the treatment of retinal and choroidal neovascularization from the University of Oxford, England. Dr. Demetriades also earned her M.D. and B.A. in Physiological Sciences from the University of Oxford.

Dr. Gabor Veres joins Vedere Bio II from BioMarin, where he served as Vice President, Head of Gene Therapy Research, focusing on AAV platform discovery and identifying new therapeutic indications in gene therapy. Prior to this role, Dr. Veres was Vice President of Pre-clinical Research at bluebird bio, where he initiated and coordinated multiple research programs including viral gene delivery to correct genetic and acquired diseases. He also led several projects from pre-clinical research to clinical development including ZYNTEGLO® (betibeglogene autotemcel) and SKYSONA™ (elivaldogene autotemcel). Prior to joining bluebird bio, Dr. Veres served as Vice President of Research and Development at Applied Genetic Technologies Corporation, a gene therapy company focused on developing treatments for rare conditions of the eye, lung and liver. Dr. Veres holds a Ph.D. in Genetics and Biochemistry from the University of Szeged, Hungary.

Mr. Mark Gaffney brings over 20 years’ experience to us and serves as our Chief Operating Officer at Vedere Bio II. He served as Chief Business Officer at Vedere Bio, which included a leading role in its acquisition by Novartis. Prior to his time with the Vedere companies, he led corporate development at Cyclerion Therapeutics, and over a ten-year career with Ironwood Pharmaceuticals, he led the corporate legal and business development functions. Mark started his legal career at Ropes & Gray, and prior to becoming a lawyer, spent five years serving in the United States Air Force. Mark holds a bachelor’s degree in mechanical engineering from the University of Pennsylvania and a law degree from Boston University.

Mr. Michael Murtagh is the Senior Vice President, Regulatory Affairs at Vedere Bio II. Prior to Vedere, he served as Vice President, Regulatory Affairs, at Astellas Gene Therapies (formerly known as Audentes Therapeutics) where he led the regulatory strategy of multiple gene therapy programs from research through clinical development. Before Astellas, Michael served as Director, Regulatory Affairs at BioMarin Pharmaceutical Inc. where he was the regulatory lead on the BRINEURA® (cerliponase alfa) and TALZENNA® (talozaprib) programs from research through clinical development. He received a B.S. in biology from the University of San Francisco.

Dr. Martina Schinke joins Vedere Bio II with nearly 20 years of experience in program leadership, strategic alliance and program management in academic, pharmaceutical, and biotech settings. Most recently, Martina provided program leadership for development of a novel class of biological drugs at Finch Therapeutics, aiming to restore microbiome functionality in Autism Spectrum Disorder and disorders of the gastrointestinal tract. Previously, Martina provided program management support for bluebird bio’s oncology franchise (now 2seventy bio) and co-led development of bluebird’s lead oncology CAR T cell therapy product ABECMA® (idecabtagene vicleucel) from research through clinical development in collaboration with Celgene/BMS. Martina was formerly with the Novartis Institute for Biomedical Research where she held senior project leadership positions over a nearly 10-year tenure and provided strategic and operational leadership for multiple Novartis early discovery and development programs in several therapeutic areas. Prior to her time at Novartis, she was overseeing the microarray facility at the Bauer Center for Genomics Research at Harvard University and was Instructor in Medicine at Harvard Medical School.

Martina holds a Ph.D. from the University in Heidelberg, Germany, and completed her postdoctoral training at the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston.

Dr. Karen Guerin is the Senior Director of Discovery Research at Vedere Bio II. Prior to joining Vedere, she was an associate director at Addgene, where she focused on AAV production and quality control. She also served as a project team leader and research investigator in gene therapy at the Novartis Institutes for BioMedical Research and was a Research Fellow at Children’s Hospital Boston. Karen holds a B.Sc in neurosciences from the University of Toulouse, an M.Sc in neurosciences and neuropharmacology from the University of Bordeaux, and a Ph.D. in vision science and molecular biology from the University of California, Berkeley.

Dr. Daniel Zimmer is Senior Director, Translational Development at Vedere Bio II. Prior to joining Vedere, he was a Senior Principal Investigator at Cyclerion, where he led the soluble guanylate cyclase stimulator discovery program, developed and executed pharmacology strategy, and contributed to clinical development of the oral soluble guanylate cyclase stimulators praliciguat and olinciguat. Prior to Cyclerion, he was a Principal Investigator at Ironwood Pharmaceuticals where he led multiple discovery programs. He holds S.B. degrees in biology and chemistry from MIT and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University.